268 related articles for article (PubMed ID: 25901716)
1. Multi-analyte analysis of non-vitamin K antagonist oral anticoagulants in human plasma using tandem mass spectrometry.
Blaich C; Müller C; Michels G; Wiesen MH
Clin Chem Lab Med; 2015 Nov; 53(12):1981-90. PubMed ID: 25901716
[TBL] [Abstract][Full Text] [Related]
2. Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method.
Du S; Harenberg J; Krämer S; Krämer R; Wehling M; Weiss C
Ther Drug Monit; 2015 Jun; 37(3):375-80. PubMed ID: 25525760
[TBL] [Abstract][Full Text] [Related]
3. Paramagnetic micro-particles as a tool for rapid quantification of apixaban, dabigatran, edoxaban and rivaroxaban in human plasma by UHPLC-MS/MS.
Wiesen MHJ; Blaich C; Streichert T; Michels G; Müller C
Clin Chem Lab Med; 2017 Aug; 55(9):1349-1359. PubMed ID: 28328524
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of the Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Warfarin in Plasma Using Ultra-Performance Liquid Chromatography with Tandem Mass Spectrometry (UPLC-MS/MS).
Noguez JH; Ritchie JC
Methods Mol Biol; 2016; 1383():21-7. PubMed ID: 26660170
[TBL] [Abstract][Full Text] [Related]
5. Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients.
Bluecher A; Meyer Dos Santos S; Ferreirós N; Labocha S; Meyer Dos Santos IM; Picard-Willems B; Harder S; Singer OC
Thromb Haemost; 2017 Feb; 117(3):519-528. PubMed ID: 28124061
[TBL] [Abstract][Full Text] [Related]
6. A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma.
Lagoutte-Renosi J; Le Poupon J; Girard A; Montange D; Davani S
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Nov; 1100-1101():43-49. PubMed ID: 30292948
[TBL] [Abstract][Full Text] [Related]
7. Validation of an LC-MS/MS method for the simultaneous quantification of dabigatran, rivaroxaban and apixaban in human plasma.
Baldelli S; Cattaneo D; Pignatelli P; Perrone V; Pastori D; Radice S; Violi F; Clementi E
Bioanalysis; 2016 Feb; 8(4):275-83. PubMed ID: 26808218
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous Determination of Dabigatran, Rivaroxaban, and Apixaban in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry.
Zhang M; Moore GA; Chin PKL
Ther Drug Monit; 2020 Jun; 42(3):473-480. PubMed ID: 32053549
[TBL] [Abstract][Full Text] [Related]
9. Using the PCI-IS Method to Simultaneously Estimate Blood Volume and Quantify Nonvitamin K Antagonist Oral Anticoagulant Concentrations in Dried Blood Spots.
Jhang RS; Lin SY; Peng YF; Chao HC; Tsai IL; Lin YT; Liao HW; Tang SC; Kuo CH; Jeng JS
Anal Chem; 2020 Feb; 92(3):2511-2518. PubMed ID: 31918541
[TBL] [Abstract][Full Text] [Related]
10. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
[TBL] [Abstract][Full Text] [Related]
11. Lupus-anticoagulant testing at NOAC trough levels.
Ratzinger F; Lang M; Belik S; Jilma-Stohlawetz P; Schmetterer KG; Haslacher H; Perkmann T; Quehenberger P
Thromb Haemost; 2016 Aug; 116(2):235-40. PubMed ID: 27075441
[TBL] [Abstract][Full Text] [Related]
12. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry.
Gous T; Couchman L; Patel JP; Paradzai C; Arya R; Flanagan RJ
Ther Drug Monit; 2014 Oct; 36(5):597-605. PubMed ID: 24695356
[TBL] [Abstract][Full Text] [Related]
13. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
[TBL] [Abstract][Full Text] [Related]
14. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study.
Harenberg J; Du S; Wehling M; Zolfaghari S; Weiss C; Krämer R; Walenga J
Clin Chem Lab Med; 2016 Feb; 54(2):275-83. PubMed ID: 26167981
[TBL] [Abstract][Full Text] [Related]
15. UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays.
Kuhn J; Gripp T; Flieder T; Dittrich M; Hendig D; Busse J; Knabbe C; Birschmann I
PLoS One; 2015; 10(12):e0145478. PubMed ID: 26699714
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study.
Gouin-Thibault I; Freyburger G; de Maistre E; Susen S; Delavenne X; Golmard JL; Gruel Y; Sié P;
Thromb Res; 2017 Oct; 158():126-133. PubMed ID: 28892657
[TBL] [Abstract][Full Text] [Related]
17. Problem-Based Review: Non Vitamin K Antagonist Oral Anticoagulants for the Acute Physician.
Thachil J; Gagg J
Acute Med; 2015; 14(2):83-9. PubMed ID: 26305087
[TBL] [Abstract][Full Text] [Related]
18. Stability of direct oral anticoagulants in whole blood and plasma from patients in steady state treatment.
McGrail R; Revsholm J; Nissen PH; Grove EL; Hvas AM
Thromb Res; 2016 Dec; 148():107-110. PubMed ID: 27835819
[TBL] [Abstract][Full Text] [Related]
19. Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants.
Ebner M; Peter A; Spencer C; Härtig F; Birschmann I; Kuhn J; Wolf M; Winter N; Russo F; Zuern CS; Blumenstock G; Ziemann U; Poli S
Stroke; 2015 Oct; 46(10):2741-7. PubMed ID: 26272385
[TBL] [Abstract][Full Text] [Related]
20. Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method.
Zhang WL; Lou D; Zhang DT; Zhang Y; Huang HJ
J Thromb Thrombolysis; 2016 Aug; 42(2):205-11. PubMed ID: 27116356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
